Abliva Competitors and Similar CompaniesClear all
Abliva's competitors and similar companies include WuXi AppTec, Molecular Partners, Brii Biosciences and Prevail Therapeutics.
 Abliva Abliva is a biotech company that discovers and develops medicines for the treatment of mitochondrial disease. |  WuXi AppTec WuXi AppTec (无锡药明康德新药开发股份有限公司, formerly known as WuXi PharmaTech) is a company that provides integrated research, development, and manufacturing solutions for drug discovery and production. |  Molecular Partners Molecular Partners is a company that develops biopharmaceutical products for serious diseases. |  Brii Biosciences Brii Biosciences researches and develops medicines for the treatment of chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. |  Prevail Therapeutics Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. | |
Founding Date | Founding Date 2000 | Founding Date 2000 | Founding Date 2004 | Founding Date 2018 | Founding Date 2017 |
Type | Type Subsidiary | Type Public | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations Lund, SE HQ | Locations Shanghai, CN HQ Beijing, CN Changzhou, CN Chengdu, CN Nanjing, CN Nantong, CN Shanghai, CN see more | Locations Zürich-Schlieren, CH HQ Cambridge, US Concord, US | Locations CN HQ Beijing, CN Durham, US San Francisco, US San Mateo, US | Locations New York, US HQ |
Employees | Employees 950% increase | Employees 39,414 | Employees 158 | Employees 8510% decrease | Employees 489% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 20.7 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 787.7 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ¥43.1b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods ¥23.8b (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit kr497k (FY, 2024) | Gross profit ¥21.3b (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income (kr90m) (FY, 2024) | Net income ¥19.3b (FY, 2025) | Net income (CHF61.7m) (FY, 2025) | Net income N/A | Net income ($63.2m) (FY, 2019) |
Funding | |||||
Total funding raised | Total funding raised $ 10.8m | Total funding raised $ 902.6m | Total funding raised N/A | Total funding raised $ 415m | Total funding raised $ 125m |
For sources of this data, please see the company profile
View Company Profiles
WuXi AppTec
HQ
Shanghai, CN
Employees
39,414
WuXi AppTec (无锡药明康德新药开发股份有限公司, formerly known as WuXi PharmaTech) is a company that provides integrated research, development, and manufacturing solutions for drug discovery and production.
View companyMolecular Partners
HQ
Zürich-Schlieren, CH
Employees
158
Molecular Partners is a company that develops biopharmaceutical products for serious diseases.
View companyBrii Biosciences
HQ
CN
Employees
85↓ 10% decrease
Brii Biosciences researches and develops medicines for the treatment of chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses.
View companyPrevail Therapeutics
HQ
New York, US
Employees
48↑ 9% increase
Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease.
View company